Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis.
“2024 was an exceptional year of execution and achievement for Globus Medical. With the NuVasive merger, we believe we created the strongest sales force and best product offering in the spine industry while maintaining our lead as the most innovative company backed up by a strong patent portfolio. During our first full year post-merger, we had strong sales growth, a record number of new product launches and the highest Enabling Technology placements to date, while accelerating our merger synergies to drive value for our shareholders,” said Dan Scavilla, president and CEO. “We remain focused on delivering product innovation, superior customer service, and operational excellence as we continue to advance patient care. 2025 is expected to be a very exciting year for product launches throughout our portfolio as we position our company for sustained growth in the broader musculoskeletal market. Globus Medical remains well positioned to achieve our vision of becoming the preeminent musculoskeletal technology company in the world by developing products that promote healing in patients."
“Our fourth quarter results demonstrated sustained growth and execution in our first full year post-merger,” commented Keith Pfeil, COO-CFO. “As we begin 2025, we seek to build upon the successes of the past year, further solidifying our foundation which will drive accelerated growth across our portfolio, as we move ahead in a manner that advances patient care while creating value for our shareholders.”
The Company established its full year 2025 revenue guidance range of $2.66 billion to $2.69 billion and fully diluted non-GAAP earnings per share range between $3.40 to $3.50.
These preliminary results are unaudited and are based on management’s initial analysis of operations for the periods ended December 31, 2024, and are therefore subject to change. The company expects to announce its fourth quarter and full year 2024 financial results on February 20, 2025, after the market close.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.